Clinical Research Directory
Browse clinical research sites, groups, and studies.
Glucagon-like-peptide-1 Receptor Agonists in Patients Receiving Maintenance Dialysis
Sponsor: Unity Health Toronto
Summary
This study aims to determine if GLP1RA is safe and tolerable in maintenance dialysis population, adherence, and feasibility of a larger definitive cardiovascular outcome trial in this population. Participants will be randomized 1:1 to either weekly subcutaneous semaglutide versus usual care and followed for 26 weeks.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-07
Completion Date
2027-09
Last Updated
2025-06-12
Healthy Volunteers
No
Interventions
Semaglutide Pen
Individuals randomized to this arm will take semaglutide once weekly. For participants receiving in-centre hemodialysis, the intervention may be administered during the dialysis session by nursing personnel based on the patient's preference.
Locations (1)
Unity Health Toronto
Toronto, Ontario, Canada